Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medacta GroupMEDGF +90.68%88 3-1 Month Momentum % is N/A% as of Aug. 17, 2026. GuruFocus rates MEDGF with a GF Score™ of 88/100 and a GF Value™ of $91.00 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 848 Medical Devices & Instruments companies, Medacta Group ranks better than 68.28% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-17), Medacta Group's 3-1 Month Momentum % is N/A%.
The industry rank for Medacta Group's 3-1 Month Momentum % or its related term are showing as below:
MEDGF's 3-1 Month Momentum % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -7.06 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Medacta Group (OTCPK:MEDGF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Medacta Group 3-1 Month Momentum % Related Terms
MEDGF vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Medacta Group's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medacta Group 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Medacta Group's 3-1 Month Momentum % falls into.
Medacta Group (OTCPK:MEDGF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medacta Group (MEDGF) has a 3-1 Month Momentum % of N/A% as of Aug. 17, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Medacta Group and its competitors. According to the industry distribution chart, Medacta Group ranks #269 out of 848 companies in the Medical Devices & Instruments industry, placing it in the top 31.7%.
Is Medacta Group's 3-1 Month Momentum % too high?
Medacta Group's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Medacta Group ranks #269 out of 848 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Medacta Group has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #269 out of 848 companies for 3-1 Month Momentum %. This puts Medacta Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Medacta Group and its competitors. Medacta Group's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (MEDGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $91.00, compared to a current price of $160.00 — trading 75.8% above its estimated fair value. The current 3-1 Month Momentum % is N/A%. Medacta Group's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Medacta Group (MEDGF), the current 3-1 Month Momentum % is N/A% as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medacta Group (MEDGF) Overvalued in 2026?
Based on GuruFocus' analysis, Medacta Group stock appears to be overvalued.
The current stock price of $160.00 is trading 75.8% above its estimated GF Value™ of $91.00.
GuruFocus considers Medacta Group to be Significantly Overvalued.
Key valuation signals for MEDGF:
3-1 Month Momentum %: N/A%
GF Value™: $91.00 vs. price of $160.00 (75.8% above fair value)
No single metric tells the full story. See the MEDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
88GF Score
Get the complete analysis for MEDGF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDGF has been successfully added to your 
